Q-omics provides the consensus-scored SMPD5 profile across patient tissues and cancer cell-line models. SMPD5 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, SMPD5 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, SMPD5 RNA expression shows 15,616 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and KIRC as cancer lineages where SMPD5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SMPD5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SMPD5 survival associations across molecular data types. SMPD5 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SMPD5 RNA expression–survival associations across cancer types. High SMPD5 expression shows unfavorable associations in ACC, UVM and COAD, but favorable associations in HNSC, READ and LGG. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for SMPD5 RNA expression.
This table summarizes SMPD5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for SMPD5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SMPD5 shows higher tumor expression in KIRC, COAD, LIHC, LUAD, STAD and HNSC. The KIRC box plot shows higher SMPD5 RNA expression in tumor versus normal tissue (log2 FC = +0.433, t-test p < 0.001).
This table shows molecular features associated with SMPD5 in patient tissues and cancer cell lines. In patient samples, SMPD5 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, SMPD5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in SKIN.
